Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12697450 | 1.00 | ADRB2 (0.41) | ADRB2ADRB1ADRB3TRPV1HDAC1 | |
| SCHEMBL1986141 | 0.91 | HDAC1 (0.38) | TRPV1HDAC1HDAC8HDAC6SLC9A1 | |
| SCHEMBL12697479 | 0.91 | HDAC1 (0.38) | TRPV1HDAC1HDAC8HDAC6SLC9A1 | |
| SCHEMBL1660660 | 0.90 | HDAC1 (0.41) | HDAC1HDAC8HDAC6PDE2APDE4B | |
| SCHEMBL1988533 | 0.90 | HDAC1 (0.53) | HDAC1HDAC8HDAC6PDE2ACSNK1D | |
| SCHEMBL12697480 | 0.90 | HDAC1 (0.53) | HDAC1HDAC8HDAC6PDE2ACSNK1D | |
| SCHEMBL12697484 | 0.90 | HDAC1 (0.41) | HDAC1HDAC8HDAC6PDE2APDE4B | |
| SCHEMBL12604735 | 0.90 | HDAC1 (0.41) | TRPV1HDAC1HDAC8HDAC6SLC9A1 | |
| SCHEMBL1986867 | 0.89 | HDAC1 (0.39) | HDAC1HDAC8HDAC6PDE2APDE4B | |
| SCHEMBL12697556 | 0.89 | HDAC1 (0.39) | HDAC1HDAC8HDAC6PDE2APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | ADRB2 341/4885ADRB1 244/4885ADRB3 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.